

---

**From:** Larry Meyers  
**Sent:** Friday, January 16, 2009 2:35 PM  
**To:** Giroir, Brett  
**Cc:** Sha-chelle Manning; Dustin Bryant; Rick Meyers  
**Subject:** Re: Hill Status

Can I share this with Cong Edwards, provided they keep the source confidential

Can I share with Hutchison's staff provided they keep it confidential?

What should we ask our people to do - if the general funds are in both bills, funding is assured, but there appears to me enough loose language to allow mischief.

How much problem is it that "flexible manufacturing" is removed? Should we fight to include it?

LM

---

**From:** "Giroir, Brett"  
**Date:** Fri, 16 Jan 2009 14:22:30 -0600  
**To:**  
**Subject:** Fw: Hill Status

Read now:-----  
Mobilize full forces

Sent using BlackBerry

---

**From:** Pat Scannon  
**To:** Giroir, Brett  
**Sent:** Fri Jan 16 14:19:51 2009  
**Subject:** Fw: Hill Status

Here is our latest summary

Sent from Pat Scannon's BlackBerry Wireless Handheld

---

**From:** Beth Rada  
**To:** Pat Scannon  
**Sent:** Fri Jan 16 12:00:07 2009  
**Subject:** RE: Hill Status  
Updated - bringing over now.

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of

this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

\_\_\_\_\_  
\_\_\_\_\_

---

**From:** Giroir, Brett  
**Sent:** Friday, January 16, 2009 3:38 PM  
**To:** 'Pat Scannon'; Diedrich, Guy  
**Cc:** 'larry.meyers@'; , 'Beth Rada'; 'Sha-chelle Manning'; Giroir, Brett  
**Subject:** Call Summary

Had a great call with Robin. Summary points:

1. He is happy with the language in House as he knows it. Appears to give \$900M in addition to his base.
2. He did not know about the Senate language. Very pleased.
3. Wants us to go full out with our delegations now. Support language on both sides. Strive to keep the full amount on the Senate side. Time to call in all the favors and pull out those incriminating pictures.
4. He wants us to share whatever we feel comfortable sharing with Pittsburgh. XOMA – you are the owner of the info now so make a choice. His main message to UPMC is that they know we need to play together, and that they understand there will be more than one facility for both national security as well as political reasons.
5. He is very concerned about JPEO-CBD. He would support Pat and I getting to Dave Williams ASAP and also the Reeves replacement. Will be a person named "Scarborough". Robin will try to find the exact name. He also would support Pat and me going the Richard Danzig, and make sure he is briefed in and can help with support.
6. HE supports Pat and I circling back with Jean Reed to make sure he supports the concept no matter what JPEO thinks
7. He wants to meet with the Geek team (Pat, myself, Pishko +/- Brett Peters, and ??? David Shanahan, ??? Rob Tenerowicz) on FEB 3 to discuss training at all levels as well as well as the mobile flexible pod concept.

Time not to screw this one up.

---

B

Brett P. Giroir, MD  
Vice Chancellor for Research,  
The Texas A&M University System;  
Adjunct Professor,  
The Bush School of Government and Public Service;  
200 Technology Way, Suite 2043  
College Station, Texas 77845-3424  
Phone: 979-458-6054  
Fax: 979-458-6044

**From:** Beth Rada  
**Sent:** Friday, January 23, 2009 5:31 PM  
**To:** Beth Rada; Pat Scannon;  
**Cc:** Tara Camper  
**Subject:** RE: Call today at 4:30pm ET/ 3:30pm CT

Brett spoke to Philomena and tried to reach Joel, but Joel was unavailable. He's currently driving and asked me to relay this message from his discussion with Philomena—UPMC has the same information we do

- o They're waiting on the Senate language
- o They're comfortable that Specter will support the funding (Brett informed them that KBH is supporting as well)
- o They have another meeting with BARDA and Robin next week and understand that there will be 3 centers
- o They agree JPEO is the biggest obstacle

## Beth

**From:** Beth Rada  
**Sent:** Friday, January 23, 2009 2:55 PM  
**To:** Pat Scannon;  
'brett.giroir@tamu.edu'  
**Cc:** Tara Camper  
**Subject:** RE: Call today at 4:30pm ET/ 3:30pm CT

Bethany and I will tag-team on this one. We'll both call his office. Bethany will call her contacts at his office. Since I'm a registered voter in PA, I'll call from my PA cell phone # and see what I can learn as a constituent.

**From:** Pat Scannon  
**Sent:** Friday, January 23, 2009 2:49 PM  
**To:** 'brett.giroir@tamu.edu'; Beth  
**Cc:** Tara Camper  
**Subject:** Re: Call today at 4:30pm ET/ 3:30pm CT

**We agree and will ask Bethany to ask about Senate wording.**

Sent from Pat Scannon's BlackBerry Wireless Handheld

**From:** larry meyers  
**To:** Beth Rada; 'Noble, Bethany A.'; Pat Scannon; jrett.Girvin@tamu.edu  
**Cc:** Tara Camper  
**Sent:** Fri Jan 23 14:42:28 2009  
**Subject:** RE: Call today at 4:30pm ET/ 3:30pm CT  
advise coordinating through Specter.

If she could contact Specter's office asking about the language and status, it would be great...

Thanks,

LM

---

**From:** Beth Rada [mailto:  
**Sent:** Friday, January 23, 2009 5:38 PM  
**To:** Noble, Bethany A.; Pat Scannon;  
Brett.Giroir@tamu.edu  
**Cc:** Tara Camper  
**Subject:** RE: Call today at 4:30pm ET/ 3:30pm CT

All,  
Spoke with Bethany. She has a number of contacts on the Senate Approps, whom we could contact:

Dem  
Inouye (HI)  
Harkin (IA)  
Mikulski (MD)  
Murray (WA)  
Feinstein (CA)  
Landrieu (LA)  
Reed (RI)

Rep  
Specter (PA)  
Domenici (NM)  
McConnell (KY)  
Shelby (AL)  
Bennett (UT)  
Brownback (KS)  
Alexander (TN)

---

**From:** Noble, Bethany A. [mailto:  
**Sent:** Friday, January 23, 2009 1:10 PM  
**To:** Pat Scannon; Beth Rada;  
Brett.Giroir@tamu.edu  
**Cc:** Tara Camper  
**Subject:** Re: Call today at 4:30pm ET/ 3:30pm CT

---

Exactly my first thought. Maybe to be named the czar re: WMD?

B

---

**From:** Pat Scannon  
**To:** Beth Rada ; Sha-Chelle Manning ; larry meyers ; Noble, Bethany A.; Giroir, Brett  
**Cc:** Tara Camper  
**Sent:** Fri Jan 23 15:44:50 2009  
**Subject:** RE: Call today at 4:30pm ET/ 3:30pm CT  
Wow, interesting stuff. Wonder where Danzig is?

**From:** Beth Rada  
**Sent:** Friday, January 23, 2009 12:38 PM  
**To:** Beth Rada; 'Sha-Chelle Manning'; 'larry meyers'; 'Noble, Bethany A.'; 'Giroir, Brett'; Pat Scannon  
**Cc:** Tara Camper  
**Subject:** RE: Call today at 4:30pm ET/ 3:30pm CT

Bethany identified the following in today's WSJ:

### **U.S. Raids Contractors Aided by Murtha**

MORE IN POLITICS »  
By JOHN R. WILKE, AUGUST COLE and T.W. FARNAM

Federal agents raided two small Pennsylvania defense contractors that were given millions of dollars in federal funding by Rep. John **Murtha**, chairman of the defense appropriations committee and one of the most powerful men in Congress.

Kuchera Industries and Kuchera Defense Systems shut down for the day after the raid by officers from the Defense Criminal Investigative Service, the Federal Bureau of Investigation and an Internal Revenue Service criminal unit.

In a statement Thursday night, the Pittsburgh U.S. attorney confirmed that offices in Windber, Johnstown and Summerhill were raided "as part of an ongoing investigation." A second federal official said that ties to lawmakers would be examined as part of the probe.

A spokesman for Mr. Murtha, Matthew Mazonkey, said, "We know nothing more than what we've read in the press today," referring to an initial report on the Web site of the Tribune-Democrat newspaper in Johnstown. Messages left last night for Kuchera executives weren't returned.

Pentagon auditors have been looking at the use of earmarks, which are special-interest spending items directed to a specific company by members of Congress. An Oct. 30, 2007, page-one story in The Wall Street Journal identified Rep. Murtha as the largest earmarker in the House.

Meanwhile, a senior Democratic lawmaker is pushing back on the Obama administration's choice for the No. 2 Pentagon official because of potential conflicts of interest and recent lobbying work for defense contractor **Raytheon Co.**

The new resistance comes a day after President Barack Obama unveiled tough lobbying rules to curtail such conflicts.

**William J. Lynn**, the nominee to become deputy secretary of defense, is a former Pentagon official and Senate staffer. He was a registered lobbyist from 2003 through June 2008 while working as a senior executive in Raytheon's Washington office.

Michigan Democratic Sen. Carl Levin, chairman of the Senate Armed Services Committee, which must approve Mr. Lynn's appointment, said Thursday that he needed more information about how the administration planned to deal with his Raytheon ties in light of the new lobbying rules.

The issue came up last week at Mr. Lynn's confirmation hearing. At the hearing, he said he would follow the highest ethical standards. Mr. Lynn, 55 years old, couldn't be reached for comment Thursday.

A White House official said Thursday that the administration will provide Sen. Levin with whatever waiver language he may need. Raytheon declined to comment.

—Yochi J. Dreazen contributed to this article.

Write to John R. Wilke at [john.wilke@wsj.com](mailto:john.wilke@wsj.com), August Cole at [august.cole@dowjones.com](mailto:august.cole@dowjones.com) and T.W. Farnam at [timothy.farnam@wsj.com](mailto:timothy.farnam@wsj.com)

---

**From:** Beth Rada

**Sent:** Friday, January 23, 2009 9:40 AM

**To:** 'Sha-Chelle Manning'; larry meyers; Noble, Bethany A.; Giroir, Brett; Pat Scannon

**Cc:** Tara Camper  
**Subject:** RE: Call today at 4:30pm ET/ 3:30pm CT

Great. We'll talk with you at 4:30pm ET/3:30pm CT.

Phone number: 00000  
Access code

Best,  
Beth

---

**From:** Sha-Chelle Manning [mailto: ]  
**Sent:** Friday, January 23, 2009 9:35 AM  
**To:** larry meyers; Beth Rada; Noble, Bethany A.; Giroir, Brett; Pat Scannon  
**Cc:** Tara Camper  
**Subject:** RE: Call today

Yes. Confirmed...

---

**From:** larry meyers [mailto:larry.meyer ]  
**Sent:** Friday, January 23, 2009 11:31 AM  
**To:** 'Beth Rada'; Sha-Chelle Manning; 'Noble, Bethany A.'; 'Giroir, Brett'; 'Pat Scannon'  
**Cc:** 'Tara Camper'  
**Subject:** RE: Call today

works for me...

LM

---

**From:** Beth Rada [mailto: ]  
**Sent:** Friday, January 23, 2009 12:06 PM  
**To:** ; Noble, Bethany A.; Giroir, Brett; larry meyers; Pat Scannon  
**Cc:** Tara Camper  
**Subject:** RE: Call today

Would everyone be available for a brief call today at 4:30pm ET (3:30pm CT and 1:30pm PT)?

---

**From:**  
**Sent:** Thursday, January 22, 2009 5:06 PM  
**To:** Beth Rada; Noble, Bethany A.; Giroir, Brett; larry meyers; Pat Scannon  
**Cc:** Tara Camper  
**Subject:** Re: Call tomorrow

Yes! Larry has shown me the light on a couple on points. We have a solid plan with backup moving forward. Many thanks and look forward to our call tomorrow. S

Sent from my BlackBerry® smartphone with SprintSpeed

---

**From:** "Beth Rada"  
**Date:** Thu, 22 Jan 2009 15:50:53 -0800  
**To:** Noble, Bethany A.

<sup>4</sup>  
; Giroir, Brett<Brett.Giroir@tamu.edu>; Sha-Chelle

Manning<  
Scannon<

**Subject:** Call tomorrow

All,

Following our phone call today, Larry and Sha-Chelle aligned their thinking on Senate strategy. Please let me know if you are available tomorrow after 11am PT/1pm CT/ 2pm ET for a brief call.

Best,  
Beth

---

~~The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.~~

---

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

---

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

TAX ADVICE DISCLAIMER: Any federal tax advice contained in this communication (including attachments) was not intended or written to be used, and it cannot be used, by you for the purpose of (1) avoiding any penalty that may be imposed by the Internal Revenue Service or (2) promoting, marketing or recommending to another party any transaction or matter addressed herein. If you would like such advice, please contact us.

Above email is for intended recipient only and may be confidential and protected by attorney/client privilege.

If you are not the intended recipient, please advise the sender immediately.

Unauthorized use or distribution is prohibited and may be unlawful.



The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

---

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

---

---

**From:** Sha-Chelle Manning  
**Sent:** Monday, January 26, 2009 11:43 AM  
**To:** Giroir, Brett; Beth Rada; Pat Scannon;  
**Subject:** RE: BARDA - no funds in the Senate version

that came from the White House – Bob and a staffer in Spectra’s office

---

**From:** Giroir, Brett [mailto:Brett.Giroir@tamu.edu]  
**Sent:** Monday, January 26, 2009 11:41 AM  
**To:** Beth Rada; Pat Scannon; Sha-Chelle Manning  
**Subject:** RE: BARDA - no funds in the Senate version

There was an email in which the Senate language at one time had \$1.2B  
Does someone have that or was that an earlier dream???

Brett P. Giroir, MD  
Vice Chancellor for Research,  
The Texas A&M University System;  
Adjunct Professor,  
The Bush School of Government and Public Service;  
200 Technology Way, Suite 2043  
College Station, Texas 77845-3424  
Phone: 979-458-6054  
Fax: 979-458-6044

---

**From:** Beth Rada [mailto:  
**Sent:** Monday, January 26, 2009 11:16 AM  
**To:** Pat Scannon; Giroir, Brett  
**Subject:** FW: BARDA - no funds in the Senate version  
**Importance:** High

All, I've been trying to access the House and Senate language all morning – I'm not sure if it's my computer or the site. Please let me know if anyone else has better luck.  
As said below from Burr's office, the Senate bill DOES NOT include any \$ for BARDA, only pandemic influenza.  
Please let us know when you are able to talk today.  
Thanks,  
Beth

Hi Beth – As you have probably seen, the Senate economic recovery package includes \$870 M for pan flu and nothing for BARDA/biodefense. I don't know what happened – the funds were in the Reid/Byrd stimulus bill a couple months ago and were included in the House package. I don't know what kind of traction you have gotten on the Senate side, but if you have any contacts, can you see what you can find out? Thanks.

<http://www.appropriations.senate.gov/>

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

---

---

**From:** Beth Rada  
**Sent:** Tuesday, January 27, 2009 7:04 PM  
**To:** Pat Scannon; Sha-Chelle Manning; Giroir, Brett; larry.meyers@  
Noble, Bethany A.; Diedrich, Guy  
**Subject:** RE: Sen Approps approves bill - next steps  
**Attachments:** FY09 stimulus letter.doc

I will be all ears at the flu meeting on Monday.

-----Original Message-----

From: Pat Scannon  
Sent: Tuesday, January 27, 2009 4:31 PM  
To: 'Sha-Chelle Manning'; Giroir, Brett; Beth Rada; larry.meyers@  
Noble, Bethany A.; Diedrich, Guy  
Subject: RE: Sen Approps approves bill - next steps

IDSA has a flu mtg in DC very soon (Mon I think). The big guys dominate and will be bragging about their message. That will be a good place to see them. Beth is attending.

-----Original Message-----

From: Sha-Chelle Manning [mailto:~  
Sent: Tuesday, January 27, 2009 4:25 PM  
To: Giroir, Brett; Beth Rada; larry.meyers@  
Noble, Bethany A.; Pat Scannon; Diedrich, Guy  
Subject: RE: Sen Approps approves bill - next steps

Pat/Brett,

Any chance either of you have a briefing deck from the Flu guys??? We need to understand their messaging/value proposition early...so we can hone our messaging...would love to get our hands on one of their briefings early...so we can hone our messaging...would love to get

Some thoughts---

We do not want to say the flu deal is bad (cannot go to war with the pharma boys yet)--- but we might mention -- of the \$\$\$ that will go to these flu cos--- only \$\$\$ will stay in the US.

We will be spending xxxx and will only last XXXX long and we still with have no capability against the greatest stated threat in the WMD report....

Also we need a new capability that we have to grow/seed here in the US with some of our more agile small and medium sized next-gen pharma cos...and building the workforce.....

5

-----Original Message-----

From: Giroir, Brett [mailto:Brett.Giroir@tamu.edu]  
Sent: Tuesday, January 27, 2009 6:10 PM

To: Beth Rada; larry.meyers(                      Noble, Bethany A.; Sha-Chelle Manning;  
Pat Scannon; Diedrich, Guy  
Subject: RE: Sen Approps approves bill - next steps

We still need the final language to see if there is any mention of manufacturing or a  
directive to SEC DHHS for a plan in 60 days.  
But yes, probably on to plan C

Brett P. Giroir, MD  
Vice Chancellor for Research,  
The Texas A&M University System;  
Adjunct Professor,  
The Bush School of Government and Public Service; 200 Technology Way, Suite 2043 College  
Station, Texas 77845-3424  
Phone: 979-458-6054  
Fax: 979-458-6044

-----Original Message-----

From: Beth Rada [mailto:  
Sent: Tuesday, January 27, 2009 5:57 PM  
To: larry.meyers(                      , Giroir, Brett; Noble, Bethany A.; Sha-Chelle Devlin  
Manning; Pat Scannon; Diedrich, Guy  
Subject: Sen Approps approves bill - next steps

Senate Approps approved bill -- 21 to 9 vote. \$870m for pan flu remains.  
<http://appropriations.senate.gov/> Full draft language is not available.

Onto Plan C.

Who will be meeting in conference? What are we going to push for?

Based on discussions today, here are some thoughts:

Option 1 - rally appropriate House & Senate members (who will be going in to conference) to  
push to keep the House \$ for BARDA but increase it by \$30m = \$460m total for BARDA (no  
mention of FM in the final language but have a separate conversation w/ BARDA that the add'l  
\$30m is for phase 1 of FM)

Option 2 - rally appropriate House & Senate members to push for the \$430m for BARDA to be  
included in the final version, with the language changed for the \$430m for BARDA to say  
something to the effect of "\$430m for advanced research and development, of which, \$30m will  
be dedicated to phase 1 of the design and initiation of the national centers for  
flexible production of MCM."

Option 3 - The opposite of Option 2 - Ask BARDA to set aside \$15m or \$30m of the total amt  
for BARDA for FM/phase 1. No legisl action. Gear up for omnibus 09 and 2010 budget.

Other options??

We can draw a number of reasons why the flu \$ won't necessarily benefit AMERICAN companies  
and stimulate job growth.

The FM Center addresses each of the following points that the Senate was asked to consider:

- \* Creating jobs.
- \* Rebuilding America's infrastructure.
- \* Improving the education of our children.

\* Improving our healthcare system, so all Americans can have access to quality treatment.

b

--  
The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all

copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. **Any views expressed in this message** are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

--  
The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. **Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited.** Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

==

## **Working Group on Pandemic Influenza Preparedness**

October 24, 2008

Dear Senator/Representative:

On behalf of the Working Group on Pandemic Influenza Preparedness, a broad-based coalition of organizations that believe that pandemic influenza poses a major threat to the nation's public health, security, and economy, and that the U.S. government's preparedness efforts should be commensurate with the threat, we write to express support for two important funding increases that were included in the economic stimulus legislation (S. 3604) considered on the Senate floor on September 26th. We urge their inclusion as part of any stimulus package considered by the 110<sup>th</sup> Congress before it adjourns.

S. 3604 provided a total increase of \$905 million increase to the Public Health and Social Services Emergency Fund. This increase would support programs crucial to the nation's public health emergency preparedness, including pandemic influenza preparedness and the Biomedical Advanced Research and Development Authority (BARDA).

The threat of pandemic influenza continues unabated. In August, Centers for Disease Control and Prevention (CDC) Director Julie Gerberding warned: "Complacency is enemy number one when it comes to preparing for another influenza pandemic." The Working Group commends Congress for its significant investment to date for pandemic preparedness activities, but additional funding is needed to complete the preparedness activities outlined in the National Strategy for Pandemic Influenza in November 2005.

Specifically, the legislation provided an additional \$363 million for one-time funding for vaccine and antiviral purchases, necessary medical supplies, and for the development of rapid diagnostics, bringing the total to \$870 million. In FY 2008, the President requested these funds, which while included in large part in the vetoed FY 2008 Labor/HHS funding measures, were not incorporated into the final FY 2008 omnibus appropriations bill. We urge Congress to provide this funding to help complete the current commitment to treatment options. We also look forward to working with Congress to continue the federal commitment to all critical elements of pandemic influenza preparedness, including state and local capacities to manage a pandemic.

Another provision included a funding increase of \$473 million for BARDA, within the Office of the Assistant Secretary for Preparedness and Response, to support advanced development and procurement of medical countermeasures for chemical, biological, radiological, and nuclear agents, as well as for pandemic influenza and other emerging infectious diseases. These threats to the nation are real. BARDA holds great potential to encourage and facilitate research and development of new biomedical countermeasures, diagnostics, and related technologies; however, the intentions of Congress and the Administration in creating BARDA are far from being realized. The small amount of funding provided to BARDA to date only has allowed the Department of Health and Human Services to establish an infrastructure to support a yet-to-be-seen robust advanced R&D

portfolio for many innovative biomedical products. The remaining \$50 million would go toward building the capacity to deliver countermeasures to the civilian population.

Again, we request your support in ensuring that this funding is included in any stimulus considered by the Congress before it adjourns for the year.

Sincerely,

American Academy of Pediatrics  
American College of Occupational and Environmental Medicine  
American Lung Association  
American Osteopathic Association  
American Public Health Association  
American Red Cross  
Association of Public Health Laboratories  
Association of State & Territorial Health Officials  
Asthma and Allergy Foundation of America  
Biotechnology Industry Organization  
Campaign for Public Health  
Center for Biosecurity, University of Pittsburgh Medical Center  
Center for Infectious Disease Research & Policy  
GlaxoSmithKline  
Infectious Diseases Society of America  
National Association of Community Health Centers  
National Association of County and City Health Officials  
Novartis Vaccines and Diagnostics, Inc.  
Planet Biotechnology  
Roche  
Sanofi Pasteur, Inc.  
Service Employees International Union  
Trius Therapeutics  
Trust for America's Health  
VaxInnate Corporation

Please direct all inquiries or comments to Jeff Levi ([jlevi@tfah.org](mailto:jlevi@tfah.org)), Kim Elliott ([kelliott@tfah.org](mailto:kelliott@tfah.org)), or Rich Hamburg ([rhamburg@tfah.org](mailto:rhamburg@tfah.org)). All can be reached by phone at 202-223-9870. Trust for America's Health is committed to sharing information with all members of the Working Group on Pandemic Preparedness or directing specific inquiries to participating organizations.



---

**From:** Giroir, Brett  
**Sent:** Thursday, January 29, 2009 11:38 AM  
**To:** Giroir, Brett  
**Subject:** FW: Sen Approps approves bill - next steps

The Committee also recognizes the need to develop flexible, multi-product, multi-technology manufacturing capabilities against biotthreat agents aside from pandemic flu. As such, the Committee recommends an additional \$120M to BARDA for flexible manufacturing facilities design, construction, and training of technical personnel.

Brett P. Giroir, MD  
Vice Chancellor for Research,  
The Texas A&M University System;  
Adjunct Professor,  
The Bush School of Government and Public Service; 200 Technology Way, Suite 2043 College  
Station, Texas 77845-3424  
Phone: 979-458-6054  
Fax: 979-458-6044

-----Original Message-----

**From:** Giroir, Brett  
**Sent:** Thursday, January 29, 2009 11:27 AM  
**To:** Diedrich, Guy  
**Subject:** RE: Sen Approps approves bill - next steps

The Committee also recognizes the need to develop flexible, multi-product, multi-technology manufacturing capabilities against biotthreat agents aside from pandemic flu. ~~AS SUCH, THE~~ Committee recommends XX\$ for BARDA for initial planning and prototyping of such manufacturing capabilities, to include at minimum facilities design and training of technical personnel.

Brett P. Giroir, MD  
Vice Chancellor for Research,  
The Texas A&M University System;  
Adjunct Professor,  
The Bush School of Government and Public Service; 200 Technology Way, Suite 2043 College  
Station, Texas 77845-3424  
Phone: 979-458-6054  
Fax: 979-458-6044

-----Original Message-----

**From:** Diedrich, Guy  
**Sent:** Thursday, January 29, 2009 11:22 AM  
**To:** Giroir, Brett  
**Subject:** FW: Sen Approps approves bill - next steps

-----Original Message-----

**From:** Beth Rada [mailto:  
**Sent:** Wednesday, January 28, 2009 4:57 PM

To: Beth Rada; Giroir, Brett; Larry.meyers  
Scannon; Sha-Chelle Devlin Manning; Diedrich, Guy  
Subject: RE: Sen Approps approves bill - next steps

} Noble, Bethany A.; Pat

Here is the Senate Approps Committee's justification for including the Pandemic Influenza funds (language taken from their report). The second paragraph is 100% industry.

#### Pandemic Influenza

The Committee has also included \$870,000,000 for pandemic influenza activities, which represents the third installment to implement the Pandemic Influenza Preparedness Strategy. The Committee recognizes that influenza vaccine production facilities may soon come online that will bring the domestic influenza vaccine capacity within reach of the targets set by the preparedness strategy by early in the next decade. However, the Committee notes that even with this additional manufacturing capacity, supply of a pandemic vaccine manufactured after the detection of a potential pandemic would be extremely limited in the first weeks and months, and not reach everyone until 6 months after production begins. The Committee encourages the Department to invest in processes, adjuvants, contingency plans, and/or vaccine strategies that could address this potential shortcoming.

The Committee is also concerned that the influenza vaccine production capacity in the United States will soon outpace demand by large numbers. The Committee encourages the Department to identify ways to increase demand for the annual influenza vaccine and to develop contingency plans to ensure that the hard-earned increase in domestic production is not short-lived.

-----Original Message-----

From: Beth Rada  
Sent: Wednesday, January 28, 2009 1:16 PM  
To: 'Giroir, Brett'; Noble,  
Bethany A.; Pat Scannon; Sha-Chelle Devlin Manning; Diedrich, Guy  
Subject: RE: Sen Approps approves bill - next steps

I copied and pasted the language of the bill that's currently on the floor of the House. Note this language is unchanged from the version we were reviewing last week - the \$420m still includes the clause "...may be used for the construction or renovation of privately owned facilities for pan flu vx and other biologics)..."

Senate language has not yet been made public.

Beth

public health and social services emergency fund

(including transfer of funds)

For an additional amount for 'Public Health and Social Services Emergency Fund' to support advanced research and development pursuant to section 319L of the Public Health Service Act, \$430,000,000: Provided, That the provisions of section 1103 of this Act shall not apply to this appropriation.

For an additional amount for 'Public Health and Social Services Emergency Fund' to prepare for and respond to an influenza pandemic, including the development and purchase of vaccine, antivirals, necessary medical supplies, diagnostics, and other surveillance tools, \$420,000,000: Provided, That the provisions of section 1103 of this Act shall not apply to this appropriation: Provided further, That products purchased with these funds may, at the discretion of the Secretary of Health and Human Services (Secretary), be deposited in the Strategic National Stockpile: Provided further, That notwithstanding section 496(b) of the Public Health Service Act, funds may be used for the construction or renovation of privately owned facilities for the production of pandemic influenza vaccine and other biologics, where the Secretary finds such a contract necessary to secure sufficient supplies of such vaccines or biologics: Provided further, That funds appropriated in this paragraph may be transferred to other appropriation accounts of the Department of Health and Human Services, as determined by the Secretary to be appropriate, to be used for the purposes specified in this sentence.

For an additional amount for 'Public Health and Social Services Emergency Fund' to improve information technology security at the Department of Health and Human Services, \$50,000,000: Provided, That the Secretary shall prepare and submit a report by not later than November 1, 2009, and by not later than 15 days after the end of each month thereafter, updating the status of actions taken and funds obligated in this and previous appropriations Acts for pandemic influenza preparedness and response activities, biomedical advanced research and development activities, Project BioShield, and Cyber Security.

-----Original Message-----

From: Giroir, Brett [mailto:Brett.Giroir@tamu.edu]  
Sent: Wednesday, January 28, 2009 7:01 AM  
To: Noble, Bethany A.; Pat Scannon; Beth Rada; Sha-Chelle Devlin Manning; Diedrich, Guy  
Subject: RE: Sen Approps approves bill - next steps

As soon as we have final language on house and/or senate, please forward to the group. First question is whether House language on NCM is broad enough to fund some manufacturing.

B

Brett P. Giroir, MD  
Vice Chancellor for Research,  
The Texas A&M University System;  
Adjunct Professor,  
The Bush School of Government and Public Service;  
200 Technology Way, Suite 2043  
College Station, Texas 77845-3424  
Phone: 979-458-6054  
Fax: 979-458-6044

-----Original Message-----

From: Larry Meyers [mailto:larry.meyers@] 7  
Sent: Tuesday, January 27, 2009 7:28 PM  
To: Noble, Bethany A.; Pat Scannon; Larry D. Meyers; Beth Rada; Giroir, 1

Brett; Sha-Chelle Devlin Manning; Diedrich, Guy  
Subject: Re: Sen Approps approves bill - next steps

I like your attitude!

LM

-----Original Message-----

From: "Noble, Bethany A." <bethany.noble@tamug.edu>

Date: Tue, 27 Jan 2009 20:27:38 -0500

To: Pat Scannon

<larry.meyers@tamug.edu>

Beth Rada

<brett.giroir@tamug.edu>

<gdiedrich@tamug.edu>

Subject: RE: Sen Approps approves bill - next steps

Odder things have happened - when I was first investigating the Senate support, my transition sources told me that there was a rumor of having all the biodefense in a separate package to highlight the new administration's strong dedication. The new BioDefense Czar has not yet been named either. In your wildest dreams do you suppose that individual will be named shortly along with the rest of the team and legislation quickly following? Would explain the PA/Murtha situation, Joel's visit to Daschle and UPMC's apparent lack of concern...

~~Grabbing at straws,~~

B

---

From: Pat Scannon [mailto:scannon@tamug.edu]

Sent: Tue 1/27/2009 7:29 PM

To: larry.meyers@tamug.edu

Beth Rada;

brett.giroir@tamug.edu; Noble, Bethany A.;

gdiedrich@tamug.edu

Subject: Re: Sen Approps approves bill - next steps

-----  
Agree - this does not sound like UPMC has it in control.

Sent from Pat Scannon's BlackBerry Wireless Handheld

----- Original Message -----

From: larry.meyers@tamug.edu

<larry.meyers@tamug.edu>

To: Beth Rada; Brett Giroir <Brett.Giroir@tamug.edu>; Noble, Bethany A.

<bethany.noble@tamug.edu>; Sha-Chelle Devlin Manning

<scannon@tamug.edu>; Guy Diedrich

<gdiedrich@tamug.edu>

Sent: Tue Jan 27 16:11:11 2009

Subject: Re: Sen Approps approves bill - next steps

Question remains - why no action by Pennsylvania's Senator?

LM

Sent via BlackBerry by AT&T

-----Original Message-----

From: "Beth Rada"

Date: Tue, 27 Jan 2009 15:56:33

To: <larry.meyers@tamu.edu> Brett  
Giroir<Brett.Giroir@tamu.edu>; Noble, Bethany  
A.<Sha-Chelle Devlin  
Manning Pat Scannon . Guy  
Diedrich<gdiedrich@tamu.edu>  
Subject: Sen Approps approves bill - next steps

Senate Approps approved bill -- 21 to 9 vote. \$870m for pan flu  
remains.  
<http://appropriations.senate.gov/> Full draft language is not available.

Onto Plan C.

Who will be meeting in conference? What are we going to push for?

Based on discussions today, here are some thoughts:

Option 1 - rally appropriate House & Senate members (who will be going  
in to conference) to push to keep the House \$ for BARDA but increase it  
by \$30m = \$460m total for BARDA (no mention of FM in the final language  
but have a separate conversation w/ BARDA that the add'l \$30m is for  
phase 1 of FM)

Option 2 - rally appropriate House & Senate members to push for the  
\$430m for BARDA to be included in the final version, with the language  
changed for the \$430m for BARDA to say something to the effect of "\$430m  
for advanced research and development, of which, \$30m will be dedicated  
to phase 1 of the design and initiation of the national centers for  
flexible production of MCM."

Option 3 - The opposite of Option 2 - Ask BARDA to set aside \$15m or  
\$30m of the total amt for BARDA for FM/phase 1. No legisl action. Gear  
up for omnibus 09 and 2010 budget.

Other options??

We can draw a number of reasons why the flu \$ won't necessarily benefit  
AMERICAN companies and stimulate job growth.

The FM Center addresses each of the following points that the Senate was  
asked to consider:

- \* Creating jobs.
- \* Rebuilding America's infrastructure.
- \* Improving the education of our children.
- \* Improving our healthcare system, so all Americans can have access to  
quality treatment.

b

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). **No confidentiality or privilege is waived or lost by any transmission error.** If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

---

---

---

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

**TAX ADVICE DISCLAIMER:** Any federal tax advice contained in this communication (including attachments) was not intended or written to be used, and it cannot be used, by you for the purpose of (1) avoiding any penalty that may be imposed by the Internal Revenue Service or (2) promoting, marketing or recommending to another party any transaction or matter addressed herein. If you would like such advice, please contact us.

Above email is for intended recipient only and may be confidential and protected by attorney/client privilege.  
If you are not the intended recipient, please advise the sender immediately.  
Unauthorized use or distribution is prohibited and may be unlawful.

--

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). **No confidentiality or privilege is waived or lost by any transmission error.** If the reader of this message is not the intended recipient, please immediately delete the e-mail and all

copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

---

**From:** Pat Scannor  
**Sent:** Wednesday, February 04, 2009 6:25 AM  
**To:** Diedrich, Guy  
**Cc:** Giroir, Brett  
**Subject:** Fw: Surprise Contact

Guy, I thought you would enjoy reading this. Tommy is the son of the nose gunner of the B24 we found in 2004.

I already hold your Governor in high regard - even so, I find this outreach to Tommy at such a busy time so extraordinary. What a special person he is.

All the best,

Pat

PS: Wil Hilton wrote the article in GQ that Tommy mentioned. He is tagging along with our team in Palau later this month.

Sent from Pat Scannon's BlackBerry Wireless Handheld

---

**From:** Tommy Doyle  
**To:** Pat Scannon  
**Sent:** Tue Feb 03 16:53:27 2009  
**Subject:** Surprise Contact

Pat,

I received a nice call from Rick Perry today to say thanks for the magazine and letter. We had a nice conversation about several things. He seems to think he can lure you to Texas. I gave my total support to his efforts. I bragged on you a lot and never lied once. I see that Wil has been added to the team. You have gathered an impressive bunch.

You know we think the world of you.

Tommy

---

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.



---

**From:** Pat Scannor  
**Sent:** Thursday, February 05, 2009 10:23 AM  
**To:** steven\_opal@brown.edu  
**Cc:** Byron Noble  
**Subject:** Fw: National facility ; Beth Rada

Update for our lobbyist . We will keep you up to date as this progresses. Thanks again, Steve.  
Pat

---

Sent from Pat Scannon's BlackBerry Wireless Handheld

---

**From:** Noble, Bethany A.  
**To:** Pat Scannon  
**Sent:** Thu Feb 05 07:49:04 2009  
**Subject:** RE: National facility  
Steve has been invaluable. We produced a brief with his thoughts (Steve approved) that are now documented. During this breather, we are going to strategize on how best to move forward but his involvement and support are on the record. We don't want to overuse him as a chit so we will stand off further pushing it for the moment but will re-engage as appropriate - until we decide for conference language and/or the Global War on Terrorism Supplemental.

B

Bethany A. Noble\*  
Director, Federal Procurement  
Buchanan Ingersoll & Rooney  
Office: 202-452-5768

\*not admitted to the practice of law

---

**From:** Pat Scannon [mailto:  
**Sent:** Thursday, February 05, 2009 10:15 AM  
**To:** Noble, Bethany A.  
**Subject:** Fw: National facility

Anything I can tell Steve?

-----  
Sent from Pat Scannon's BlackBerry Wireless Handheld

----- Original Message -----

**From:** Pat Scannon  
**To:** 'steven\_opal@brown.edu' <steven\_opal@brown.edu>  
**Sent:** Wed Feb 04 17:28:47 2009  
**Subject:** Re: National facility

Steve, we are still working with Senator Reed's office. The timing may occur after the senate vote as it goes to conference. I will check further and get back to you soon. Thanks again for your help so far.

P

---

Sent from Pat Scannon's BlackBerry Wireless Handheld

----- Original Message -----

From: Opal, Steven <Steven\_Opal@brown.edu>

To: Pat Scannon

Sent: Wed Feb 04 16:44:01 2009

Subject: Re: National facility

Pat,

Any word on this?

I have been working with Senator Reed's office on this a bit.

S. Opal

-----Original Message-----

From: Pat Scannon

To: Steven Opal

To:

Cc: Beth Rada

Cc: .

Cc: brett.giroir@tamu.edu

Subject: National facility

Sent: Feb 2, 2009 11:21

Dear Steve,

I deeply appreciate your reception to my rather compressed phone call just now. Brett and I are excited about the possibilities of linking Texas A&M and your Center for Emerging infectious Diseases as part of this biodefense campus.

You will see copied Bethany Noble out of DC whose office has close connections with Senator Reed. Bethany will work to make the connection with the senator's office today or tomorrow. Things, as you can sense, are happening rapidly.

I am adding your, Bethany's and Brett's cell phones for connections as needed.

We are all looking forward to the possibilities.

All the best at SCCM,  
Warmest regard, Pat

Dr. Steve Opal: 14015751814

Ms. Bethany Noble: (202) 251-0004

Dr. Brett Giroir: 777

~~Sent from Pat Scannon's BlackBerry Wireless Handheld~~

---

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

---

---

**From:** John Kane  
**Sent:** Thursday, February 05, 2009 5:18 PM  
**To:** 'Beth Rada'; Giroir, Brett; 'Sha-Chelle Mannino'  
**Attachments:** bardacolloquy-brownbackadd.doc

Diedrich, Guy; 'Pat Scannon'

Here is what Beth and I think is going to be in the record but we got Brownback in the colloquy.

S. 1

**The American Recovery and Reinvestment Act of 2009**

Colloquy

Biodefense Medical Countermeasures

Sen. Daniel K. Inouye, Sen. Tom Harkin, Sen. Robert P. Casey, Jr., Sen. Arlen Specter, Sen. Sam Brownback

SEN. CASEY: I rise to engage the esteemed Chairman of the Appropriations Committee, Senator Daniel Inouye; Senator Tom Harkin, Chairman of the Labor, Health & Human Services, and Education Subcommittee; my Pennsylvania colleague, Senator Arlen Specter ; and my Kansas colleague, Senator Sam Brownback in a colloquy regarding funding for creating capabilities to develop and manufacture biodefense medical countermeasures.

As the Chairmen and Senator Specter are aware, our country faces the rising threat of a bioterrorist attack against the U.S. homeland. Indeed, most experts agree that a bioweapons attack could be launched against the United States within the next few years. Such an event could inflict civilian casualties on a scale that would threaten the viability of a city's or region's key institutions and impose a widespread sense of vulnerability across the country and internationally.

Moreover, President Obama has stated on numerous occasions that the bioterrorist threat is real and increasing. And, I believe, he will make responding to such a threat a key element of his national security strategy.

SEN. HARKIN: I agree with my colleague from Pennsylvania that our nation faces this growing threat and that we must respond accordingly.

SEN. SPECTER: Mr. Chairman, the bill you have brought before the Senate includes funding to respond to many economic and security issues facing our country today, and I congratulate him on his tremendous effort. In particular, the bill includes funding for the Health and Human Services Department pandemic flu program, which falls under the Subcommittee on which I have dedicated much of my service to the country. Unfortunately, the Senate bill

does not identify specific funding for HHS to address bioterrorism and the development and production of biodefense medical countermeasures.

SEN. BROWNBACK: I agree with my colleagues Mr. Chairman that the bill you have brought before us addresses many impending needs. This matter we are discussing not only addresses a critical matter of national security by creating the capability to develop enough medical counter measures to treat the US population in the event of a terrorist attack, but it would expand domestic jobs and domestic infrastructure in the biotechnology industry. Like Senator Specter addressed previously, this bill does not identify specific funding for these needs.

I am sure my colleagues from Pennsylvania and Iowa would join me in concluded the best way of addressing these threats is for partnerships between the academic, industry and government sectors. Academically-affiliated, privately-operated National Centers of Excellence for Flexible Manufacturing of Medical Counter Measures are the answer to developing, sustaining, and integrating our country's biodefense portfolio under the Biomedical Advanced Research and Development Authority.

SEN. INOUE: That is correct. I recognize the importance of these investments. It is my understanding that the House version of the recovery bill includes funding for biodefense and medical countermeasures within the Public Health and Social Services Emergency Fund.

SEN. SPECTER: A key component of preparedness is the availability of effective preventive and therapeutic drugs and vaccines to counter diseases caused by man-made attacks and public health threats. Identifying and funding the means to acquire these drugs and vaccines is an issue that I believe the Appropriations Committee and the Labor-HHS Subcommittee should urgently address.

SEN. CASEY: Mr. Chairman, it is my understanding that the House version of the recovery bill includes funding for biodefense and medical countermeasures within the Public Health and Social Services Emergency Fund. I am sure my colleagues would join me in urging you to agree to include funding for capabilities to support the development and production of biodefense medical countermeasures to address the bioterrorism threat in the conference report of this bill. We believe there is no better use of American taxpayers dollars to both create high-quality jobs, retain

biotechnology expertise domestically, and address a terrible threat to our nation.

SEN. INOUE: I thank my colleagues for raising this important issue with me today. I intend to work with you and the members of the conference committee to identify funding to develop and produce biodefense medical countermeasures.

SEN. HARKIN: The capability that we are discussing is vital to our Nation's defense. It would also be a critical source of innovation, developing novel countermeasures faster and cheaper. I will also work with you during conference.

**From:** Robert Tenerowitz  
**To:** Groir, Brett; Cumpton, J. Brett  
**Cc:** Pat Scannon; Cal McGoogan  
**Subject:** NCTM team membership from XOMA  
**Date:** Wednesday, July 08, 2009 9:46:18 AM

---

Hi Brett/Brett,

Given some of the discussion at the kick-off meeting regarding the need to incorporate more quality systems thinking right at the very beginning (which I totally agree), I'd like to recommend that Cal McGoogan, our VP of Quality and Facilities, become XOMA's lead participant on the project. I think Cal is the most appropriate lead at this time given where we are on the development time line. I will continue to be very much involved on the project, including participation on the process subteam and would also plan to participate in the design and functionality of the modular units...and wherever else I can contribute.

Let me know if you have any questions or comments on this. I think Cal will be a great addition to the team.

Thanks,  
Rob

---

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

**From:** [Cal McGoogan](#)  
**To:** Giroir, Brett  
**Cc:** [Cumpton, J. Brett](#)  
**Subject:** FW: XOMA Press Release  
**Date:** Tuesday, December 22, 2009 10:18:26 AM  
**Importance:** High

---

Hi Brett,

Wanted to make sure you saw this press release about the elimination of XOMA's "going concern". Pat is trying to set up a meeting with you next week.

Happy holidays,  
Cal McGoogan  
Vice President, Quality and Facilities  
XOMA (US) LLC

---

## **XOMA Reports Removal of "Going Concern" Qualification**

---

BERKELEY, Calif., December 22, 2009: XOMA Ltd. (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that, as a result of an improvement in the Company's financial status and in particular its full repayment of an outstanding loan, at the Company's request, its independent registered public accounting firm, Ernst & Young LLP, has agreed to remove a qualification regarding the Company's ability to continue as a going concern in an updated report on the Company's financial statements for the fiscal year ended December 31, 2008. The "going concern" qualification was included earlier this year based on the need for the Company to repay or restructure its then-outstanding loan from Goldman Sachs Specialty Lending Holdings, Inc., as a result of the cessation of royalties from sales of RAPTIVA® due to an unexpected withdrawal of RAPTIVA® from the market in the first half of 2009. Today, the Company filed updated audited financial statements for the fiscal year ended December 31, 2008 along with the updated report of Ernst & Young with the Securities and Exchange Commission with a current report on Form 8-K.

### **About XOMA**

XOMA discovers, develops and manufactures novel antibody therapeutics for its own proprietary pipeline as well as through license and collaborative agreements with pharmaceutical and biotechnology companies, and under its contracts with the U.S. government. The company's proprietary product pipeline includes:

- XOMA 052, an anti-IL-1 beta antibody in Phase 2 clinical development for Type 2 diabetes, Type 1 diabetes and cardiovascular disease, with potential for the treatment of a wide range of inflammatory conditions

XOMA 3AB, an antibody candidate in pre-IND studies to neutralize the botulinum toxin, among the most deadly potential bioterror threats, under development through funding provided by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health

A preclinical pipeline with candidates in development for inflammatory, autoimmune and



oncologic diseases

In addition to its proprietary pipeline, XOMA develops products with premier pharmaceutical companies including Novartis AG, Merck & Co., Inc. and Takeda Pharmaceutical Company Limited.

XOMA has multiple revenue streams resulting from the licensing of its antibody technologies, product royalties, development collaborations and biodefense contracts. XOMA's technologies have contributed to the success of marketed antibody products, including LUCENTIS(r) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(r) (certolizumab pegol) for rheumatoid arthritis and Crohn's disease.

The company has a premier antibody discovery and development platform that incorporates an unmatched collection of antibody phage display libraries and proprietary Human Engineering(tm), affinity maturation, Bacterial Cell Expression (BCE) and manufacturing technologies. BCE is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. As a result, more than 50 pharmaceutical and biotechnology companies have signed BCE licenses, and several licensed product candidates are in clinical development.

XOMA has a fully integrated product development infrastructure, extending from pre-clinical science to approval, and a team of about 200 employees at its Berkeley, California location. For more information, please visit <http://www.xoma.com>.

The XOMA Ltd. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=5960>

### Forward-Looking Statements

Certain statements contained herein concerning product development or that otherwise ~~relate~~ to future periods are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market.

These risks, including those related to inability to comply with NASDAQ's continued listing requirements, the declining and generally unstable nature of current economic conditions; the results of discovery and pre-clinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); changes in the status of existing collaborative relationships; the ability of collaborators and other partners to meet their obligations; XOMA's ability to meet the demands of the United States government agency with which it has entered into its government contracts; competition; market demands for products; scale-up and marketing capabilities; availability of additional licensing or ~~collaboration~~ opportunities; international operations; share price volatility; XOMA's financing needs and opportunities; uncertainties regarding the status of biotechnology patents; uncertainties as to the costs of protecting intellectual property; and risks associated with XOMA's status as a Bermuda company, are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings. Consider such risks carefully when considering XOMA's prospects.

---

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s).

---

No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

**From:** Pat Scannon  
**To:** Cumpton, J. Brett; ; DeLuca, Warren; Diedrich, Guy;  
; Gay, Vergel L.; Giroir, Brett; Shanks,  
LauraLee M.; ; Vanegas, Jorge; Karr, Bruce; Kent, Gary; Knight, Katherine R.;  
; Pishko, Michael; Pollard, Claudia; Ramirez, René; Ravey, Linda; Rhea, Chuck M.;  
; Sanchez, Jeana F.; Schmid, Peter;  
Robert Tenerowicz  
**Cc:** FPC Projects: 01-3046 National Center for Therapeutics Manufacturing  
**Subject:** Re: Kick-off meeting update  
**Date:** Friday, June 19, 2009 1:02:36 PM

---

Please add Rob Tenerowicz from XOMA who will be attending. Thanks!

Pat

-----  
Sent from Pat Scannon's BlackBerry Wireless Handheld

---

**From:** Cumpton, J. Brett  
**To:** Anderson, Bruce ; Caffey, Kevin ; Cumpton, J. Brett ; DeLuca, Warren ; Diedrich, Guy ; Ferguson, James T. ; Gay, Vergel L. ; Giroir, Brett ; Glowacki, Joe ; Goworek, Bob ; Hanks, LauraLee ; Holtz, Barry ; Jorge Vanegas 2 ; Karr, Bruce ; Kent, Gary ; Knight, Katherine R. ; Kornberg, Daniel M. ; Larry W. M. D. Kwak Ph. D. ; Lasarsky, Phil ; McGuire, Daniel M. ; Mendyk, Joseph K. ; Pishko, Michael ; Pollard, Claudia ; Ramirez, Rene ; Ravey, Linda ; Rhea, Chuck M. ; Rosenberg, Dan ; Sanchez, Jeana F. ; Pat Scannon; Schmid, Peter ; Shanahan, David ; Shook, Michael J. ; Shook, Mike ; Strong, Andrew L. ; Vanegas, Jorge ; Wallace, Russell E.  
**Cc:** FPC Projects: 01-3046 National Center for Therapeutics Manufacturing <01-3046NationalCenterforTherapeuticsManufacturing@sagomail.tamus.edu>  
**Sent:** Fri Jun 19 10:57:30 2009  
**Subject:** Kick-off meeting update

Team,

We are sending this follow-up email to remind each of you that we have an all day kick-off meeting (8:30 to 4:30 on Thursday, June 25, 2009) for the National Center for Therapeutics Manufacturing (NCTM) project next week. The meeting is in our TAMU system building FP&C conference room "A" and will start promptly at 8:30. We have attached an agenda, still in draft form, in case we have missed an important detail that should be included. We have also attached a "first participant distribution matrix", with each of your contact information and we would like each of

you to review and make any necessary corrections. If you have any comments please send them to me (Brett Cumpton) for review and appropriate action.

Several housekeeping items:

- The tour that we are taking in the morning of the 25th, leaving no later than 9:00am, will require some safety measures on our part. Each of you need to wear solid leather close-toed shoes or boots, men's and women's leather dress shoes are acceptable (no running shoes, tennis shoes, sandals, no open toed shoes, etc.). You will also be required to listen to a 10 minute safety presentation and wear safety glasses and a hard hat during the tour, which we will provide. There can be no exceptions to these safety rules.

Some of you have been added to the invitation list and did not receive the original invitation, please do not let this fact dissuade you from attending as you would not be invited unless you were

important to the process.

**Please remember, all information contained in this email and all future correspondence for this project will need to remain confidential and shall not be shared with anyone outside of the listed participants.**

Map & Directions to the  
Texas A&M System Building  
<http://www.tamus.edu/contact/>

Thanks,

J. Brett Cumpton  
HSC/Central Area - Architectural Project Manager  
Department of Facilities Planning and Construction  
The Texas A&M University System  
200 Technology Way, Suite 1162,  
College Station, Texas 77845  
Work - (979)458-7005  
[bret-cumpton@tamu.edu](mailto:bret-cumpton@tamu.edu)

---

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

**From:** Giroir, Brett  
**To:** "Rosenberg, Dan"; Cumpton, J. Brett; Meyer, Robert J.; Shanks, LauraLee M.; Ramirez, René; Vanegas, Jorge; Pishko, Michael; ; "Lasarsky, Phil"; "Mark Sappington"; "Saeed Eslaminejad"; ; "Anwar Hassan"; "Glowacki, Joseph P - (TEXAS)"; "Goworek, Robert - (SOM)"; "Mendyk, Joseph K - (TEXAS)"; "Kristopher T. McGraw"; "Ferguson, Jim"; "Daniel Kornberg"; Khalsa, Guruatma; ; "cmooney@tamu.edu"; "Trowbridge, Allan"; "c-noynaert@tamu.edu"; Bielałowicz, Marvin; ;  
**Subject:** RE: NCTM - Site Studies 14B, 15B & 16B  
**Date:** Tuesday, October 06, 2009 3:50:32 PM

---

I think I am still a big fan of 11E, with the plan to put in all the lakes as drawn. Or perhaps 11E shifted slightly to the East as tolerable by the Corps of Engineers. Did we identify a problem with that concept?

What I like:

1. Classrooms and gathering areas will overlook lake. Will be great whether CVM develops building on the other side or keeps is pastoral
2. Service areas are hidden behind trees, as is the "ugly" part of the building.
3. Parking close and convenient. If there are less parking spaces, we can potentially extend TIPS parking as I understood the discussion.

Brett P. Giroir, MD  
 Vice Chancellor for Research,  
 The Texas A&M University System;  
 Research Professor, Dwight Look College of Engineering;  
 Adjunct Professor, The Bush School of Government and Public Service;  
 200 Technology Way, Suite 2043  
 College Station, Texas 77845-3424  
 Phone: 979-458-6054  
 Fax: 979-458-6044

**From:** Rosenberg, Dan  
**Sent:** Tuesday, October 06, 2009 1:21 PM  
**To:** Giroir, Brett; Cumpton, J. Brett; Meyer, Robert J.; Shanks, LauraLee M.; Ramirez, René; Vanegas, Jorge; Pishko, Michael; ; "Lasarsky, Phil"; Mark Sappington; Saeed Eslaminejad; Anwar Hassan; Glowacki, Joseph P - (TEXAS); Goworek, Robert - (SOM); Mendyk, Joseph K - (TEXAS); Kristopher T. McGraw; Ferguson, Jim; Daniel Kornberg; Khalsa, Guruatma; Bielałowicz, Marvin; cmooney@tamu.edu; Trowbridge, Allan; c-noynaert@tamu.edu;  
**Subject:** NCTM - Site Studies 14B, 15B & 16B

Team,

Attached are a three additional Site Studies for consideration. Listed below are advantages/disadvantages for each.

#### Site Study 14B

##### Pros

Existing creek to remain.

Academic / Research functions are facing east, towards TIPS.

Future building can be developed with shared Service Yard.

Service Yard and Dock Area are out of public view.

Lot to the west of Discovery Drive can accommodate future parking needs and overflow parking for TIPS.

Additional 2.5 acres to the immediate south of NCTM is available for parking or bldg expansion.

Pedestrian connection to TIPS and TIGM.

#### **Cons**

Parking is remote and located across the creek.

A portion of the NCTM site encroaches onto the Vet Med Park.

Vehicular / pedestrian bridge required.

Lengthy utility extension from TIPS.

A box culvert expansion and vehicular bridge are required for future development.

Master plan development may have views of NCTM service yard area (could be screened).

### **Site Study 15B**

#### **Pros**

Existing creek to remain.

Academic / Research functions are facing east, towards TIPS.

Service Yard and Dock Area are out of public view.

1 acre available to the south of NCTM for parking expansion.

Potential building expansion area available at the west end of the site.

Pedestrian connection to TIPS and TIGM.

Lot to the west of Discovery Drive can accommodate future parking needs and overflow parking for TIPS.

Site does not encroach onto the Vet Med Park.

#### **Cons**

Parking is remote and located across the creek.

Vehicular / pedestrian bridge required.

Lengthy utility extension from TIPS.

A box culvert expansion and vehicular bridge are required for future development.

### **Site Study 16B**

#### **Pros**

Existing creek to remain.

Academic / Research functions are facing south, towards TIPS and TIGM.

Pedestrian connection to TIPS and TIGM.

Utility extension from TIPS is minimized.

Service Yard and Dock Area can be screened and out of public view.

Parking is located in close proximity to the building.

Expansion potential to the north and east of NCTM.

#### **Cons**

The entire NCTM site occurs in the Vet Med Park and will require alteration to the site boundaries.

Vehicular / pedestrian bridge required.

A longer access road from Raymond Stotzer Pkwy is required.

Views to lake features for future master planned development are lost due to building orientation.

Sincerely,

Daniel E. Rosenberg, Architect  
Senior Associate, AIA, LEED AP

619 231 0751

[www.fpbarch.com](http://www.fpbarch.com)

FERGUSON  
PAPE  
BALDWIN  
ARCHITECTS

701 B STREET SUITE 200 SAN DIEGO CA 92101

**From:** Cal McGoogan  
**To:** Cumpton, J. Brett; Robert Tenerowicz; Giroir, Brett  
**Cc:** Pat Scannon; FPC Projects: 01-3046 National Center for Therapeutics Manufacturing; Schmid, Peter  
**Subject:** RE: NCTM team membership from XOMA  
**Date:** Monday, July 13, 2009 1:06:38 PM

---

Brett,  
Here is my info:

**Cal McGoogan, MBA**

Vice President, Quality and Facilities  
XOMA (US) LLC  
2910 7<sup>th</sup> St  
Berkeley, CA 94710  
Phone: 510-204-7661  
Fax: 510-644-0539  
E-mail:

Best regards,  
Cal McGoogan

---

**From:** Cumpton, J. Brett [mailto:Brett-Cumpton@tamu.edu]  
**Sent:** Monday, July 13, 2009 7:41 AM  
**To:** Robert Tenerowicz; Giroir, Brett  
**Cc:** Pat Scannon; Cal McGoogan; FPC Projects: 01-3046 National Center for Therapeutics Manufacturing; Schmid, Peter  
**Subject:** RE: NCTM team membership from XOMA

Rob,  
Send me all of his information so I can update my contacts information. I will add him to the invite list.

Thanks,

J. Brett Cumpton  
HSC/Central Area - Architectural Project Manager  
Department of Facilities Planning and Construction  
The Texas A&M University System  
200 Technology Way, Suite 1162,  
College Station, Texas 77845  
Work - (979)458-7005  
t-cumpton@tamu.edu  
bret

**From:** Robert Tenerowicz [mailto:  
**Sent:** Wednesday, July 08, 2009 9:46 AM  
**To:** Giroir, Brett; Cumpton, J. Brett  
**Cc:** Pat Scannon; Cal McGoogan  
**Subject:** NCTM team membership from XOMA



---

Hi Brett/Brett,

Given some of the discussion at the kick-off meeting regarding the need to incorporate more quality systems thinking right at the very beginning (which I totally agree), I'd like to recommend that Cal McGoogan, our VP of Quality and Facilities, become XOMA's lead participant on the project. I think Cal is the most appropriate lead at this time given where we are on the development time line. I will continue to be very much involved on the project, including participation on the process subteam and would also plan to participate in the design and functionality of the modular units...and wherever else I can contribute.

Let me know if you have any questions or comments on this. I think Cal will be a great addition to the team.

Thanks,  
Rob

---

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

---



---

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

---

**From:** Tara Camper  
**To:** Cumpton, J. Brett  
**Cc:** Pollard, Claudia  
**Subject:** RE: Rob Tenerowicz info  
**Date:** Friday, June 19, 2009 9:50:35 PM

---

Dear Mr. Cumpton,

Sorry for the delay in getting you Mr. Tenerowicz' information (please see below as I filled in the missing information). Please let me know if you need anything else. Have a wonderful weekend.

Kind Regards,

**Tara Camper**

Executive Assistant to:

Dr. Patrick J. Scannon, Executive VP and Chief Medical Officer  
Dan Cafaro, VP Regulatory Affairs and Compliance

**XOMA**

2910 Seventh Street  
Berkeley, CA 94710  
Direct Telephone: 510.204.7491  
Fax: 510.843.4127  
Email:  
Web: [www.xoma.com](http://www.xoma.com)



Before printing, think about the environment

**From:** Pollard, Claudia [mailto:CPollard@tamu.edu]  
**Sent:** Friday, June 19, 2009 2:13 PM  
**To:** Tara Camper  
**Subject:** Fw: Rob Tenerowicz info

Tara,  
Can you please respond for me to Cumpton?  
Claudia

---

**From:** Cumpton, J. Brett  
**To:** Pollard, Claudia  
**Cc:** FPC Projects: 01-3046 National Center for Therapeutics Manufacturing  
**Sent:** Fri Jun 19 15:59:28 2009  
**Subject:** Rob Tenerowicz info

Claudia,  
Can you fill in the blanks?

\_\_\_\_\_

**Facility Consultant**  
**Rob Tenerowicz**  
Title: Vice President, Operations  
XOMA  
2910 Seventh Street  
Berkeley, CA 94710  
Phone: (510) 204-7279  
Fax: (510) 649-7610

[www.xoma.com](http://www.xoma.com)

Thanks,

J. Brett Cumpton  
HSC/Central Area - Architectural Project Manager  
Department of Facilities Planning and Construction  
The Texas A&M University System  
200 Technology Way, Suite 1162,  
College Station, Texas 77845  
Work - (979)458-7005  
[brett-cumpton@tamu.edu](mailto:brett-cumpton@tamu.edu)

---

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

**From:** Giroir, Brett  
**To:** "Ferguson, Jim"; "Rosenberg, Dan"; Cumpston, J. Brett; FPC Projects: 01-3046 National Center for Therapeutics Manufacturing; Whitney, Bruce; "Anderson, Bruce"; Baron, Allan; Barwick, Don; "Bertz, Mark"; Bielowicz, Marvin; Bruner Jr., Homer; "Clement, Weldon"; "Cutler, John E."; Dew, Tom; "Duncan, Debra"; Ellerbrock, Joseph A.; "Enloe, David"; "Eslaminejad, Saeed"; Evans, Gordon; Fossum, Theresa W.; Fox, Russell D.; Frosch, Charles; Gay, Vergel L.; "Glowacki, Joe"; "Godkin, Blake S."; "Goworek, Bob"; Hall, Ken; "hansen, Bob"; Happ, John; "Harrison, James B."; Hartman, Robert L.; "Hassan, Anwar"; Hodge, Steve; "Holtz, Barry"; Karr, Bruce; "Kay, Mack"; Khalsa, Guruatma; "Kornberg, Daniel M."; "Krause, Clayton"; "Kwak W. M. D. Ph. D., Larry"; "Lasarsky, Phil"; "Lauderback, Truman"; "Mahendra, Anu"; Mann, George; "McCready, Scott"; "McGoogan, Cal"; "McGraw, Kristopher"; Menchaca, Eddie; "Mendyk, Joseph K."; Meyer, Chris; Meyer, Robert J.; "Mironova, Lyudmila"; Mooney, Catherine; "Moustapha, Harb"; "Noynaert, Chris"; "Parikh, Vimal"; "Perez, Eric"; Peters, Brett; Pishko, Michael; Pollard, Claudia; Rainer, James B; Ramirez, René; Ravey, Linda; Rhea, Chuck M.; Riley, Jim; Salsman, John M; Sanchez, Jeana F.; "Sappington, Mark"; "Scannon, Patrick (Pat) J."; Schmid, Peter; "Shanahan, David"; Shanks, LauraLee M.; Sippial, Charles A; "Slaney, Scott"; "Swick, Les"; "Tenerowicz, Rob"; "Trowbridge, Allan"; Wallace, Russell E.; "Williams, Belinda"; "Williams, Les"; Williams, Richard; "Wurbs, Frank"  
**Cc:** Ravey, Linda  
**Subject:** RE: Schematic Design and Project Schedule Meeting for NCTM  
**Date:** Tuesday, November 17, 2009 7:27:01 PM  
**Attachments:** image001.png

I was just looking for a visual that we might put forward on the TIPS opening BIG EVENT on December 3.

Brett P. Giroir, MD  
 Vice Chancellor for Research,  
 The Texas A&M University System;  
 Professor, College of Medicine, Texas A&M Health Science Center;  
 Research Professor, Dwight Look College of Engineering;  
 Adjunct Professor, The Bush School of Government and Public Service;  
 200 Technology Way, Suite 2043  
 College Station, Texas 77845-3424  
 Phone: 979-458-6054  
 Fax: 979-458-6044

]

**From:** Ferguson, Jim [mailto:  
**Sent:** Tuesday, November 17, 2009 7:06 PM  
**To:** Giroir, Brett; Rosenberg, Dan; Cumpston, J. Brett; FPC Projects: 01-3046 National Center for Therapeutics Manufacturing; Whitney, Bruce; Anderson, Bruce; Baron, Allan; Barwick, Don; Bertz, Mark; Bielowicz, Marvin; Bruner Jr., Homer; Clement, Weldon; Cutler, John E.; Dew, Tom; Duncan, Debra; Ellerbrock, Joseph A.; Enloe, David; Eslaminejad, Saeed; Evans, Gordon; Fossum, Theresa W.; Fox, Russell D.; Frosch, Charles; Gay, Vergel L.; Glowacki, Joe; Godkin, Blake S.; Goworek, Bob; Hall, Ken; hansen, Bob; Happ, John; Harrison, James B.; Hartman, Robert L.; Hassan, Anwar; Hodge, Steve; Holtz, Barry; Karr, Bruce; Kay, Mack; Khalsa, Guruatma; Kornberg, Daniel M.; Krause, Clayton; Kwak W. M. D. Ph. D., Larry; Lasarsky, Phil; Lauderback, Truman; Mahendra, Anu; Mann, George; McCready, Scott; McGoogan, Cal; McGraw, Kristopher; Menchaca, Eddie; Mendyk, Joseph K.; Meyer, Chris; Meyer, Robert J.; Mironova, Lyudmila; Mooney, Catherine; Moustapha, Harb; Noynaert, Chris; Parikh, Vimal; Perez, Eric; Peters, Brett; Pishko, Michael; Pollard, Claudia; Rainer, James B; Ramirez, René; Ravey, Linda; Rhea, Chuck M.; Riley, Jim; Salsman, John M; Sanchez, Jeana F.; Sappington, Mark; Scannon, Patrick (Pat) J.; Schmid, Peter; Shanahan, David; Shanks, LauraLee M.; Sippial, Charles A; Slaney, Scott; Swick, Les; Tenerowicz, Rob; Trowbridge, Allan; Wallace, Russell E.; Williams, Belinda; Williams, Les; Williams, Richard; Wurbs, Frank  
**Subject:** RE: Schematic Design and Project Schedule Meeting for NCTM

We're currently working on 3D design for the entire building with early views to be shared this Thursday. A more substantial BIM design effort will be put in immediately following

the floor plan approvals.

Jim

---

**From:** Giroir, Brett [mailto:Brett.Giroir@tamu.edu]

**Sent:** Tuesday, November 17, 2009 2:32 PM

**To:** Rosenberg, Dan; Cumpton, J. Brett; FPC Projects: 01-3046 National Center for Therapeutics Manufacturing; Whitney, Bruce; Anderson, Bruce; Baron, Allan; Barwick, Don; Bertz, Mark; Bielamowicz, Marvin; Bruner Jr., Homer; Clement, Weldon; Cutler, John E.; Dew, Tom; Duncan, Debra; Ellerbrock, Joseph A.; Enloe, David; Eslaminejad, Saeed; Evans, Gordon; Ferguson, Jim; Fossum, Theresa W.; Fox, Russell D.; Frosch, Charles; Gay, Vergel L.; Glowacki, Joe ; Godkin, Blake S.; Goworek, Bob; Hall, Ken; hansen, Bob; Happ, John; Harrison, James B.; Hartman, Robert L.; Hassan, Anwar; Hodge, Steve; Holtz, Barry; Karr, Bruce; Kay, Mack ; Khalsa, Guruatma; Kornberg, Daniel M. ; Krause, Clayton; Kwak W. M. D. Ph. D., Larry ; Lasarsky, Phil; Lauderback, Truman; Mahendra, Anu; Mann, George; McCready, Scott; McGoogan, Cal ; McGraw, Kristopher; Menchaca, Eddie; Mendyk ,Joseph K.; Meyer, Chris; Meyer, Robert J.; Mironova, Lyudmila; Mooney, Catherine; Moustapha, Harb ; Noynaert, Chris ; Parikh, Vimal; Perez, Eric; Peters, Brett; Pishko, Michael; Pollard, Claudia; Rainer, James B; Ramirez, René; Ravey, Linda; Rhea, Chuck M.; Riley, Jim; Salsman, John M; Sanchez, Jeana F.; Sappington, Mark ; Scannon, Patrick (Pat) J.; Schmid, Peter; Shanahan, David; Shanks, LauraLee M.; Sippial, Charles A; Slaney, Scott; Swick, Les; Tenerowicz, Rob ; Trowbridge, Allan; Wallace, Russell E.; Williams, Belinda; Williams, Les; Williams, Richard; Wurbs, Frank

**Subject:** RE: Schematic Design and Project Schedule Meeting for NCTM

When will we have the most basic 3D design or color mock-up of what this will look like?

Brett P. Giroir, MD

Vice Chancellor for Research,

The Texas A&M University System;

Professor, College of Medicine, Texas A&M Health Science Center;

Research Professor, Dwight Look College of Engineering;

Adjunct Professor, The Bush School of Government and Public Service;

200 Technology Way, Suite 2043

College Station, Texas 77845-3424

Phone: 979-458-6054

Fax: 979-458-6044

---

**From:** Rosenberg, Dan [mailto:

**Sent:** Monday, November 16, 2009 4:16 PM

**To:** Cumpton, J. Brett; FPC Projects: 01-3046 National Center for Therapeutics Manufacturing; Whitney, Bruce; Anderson, Bruce; Baron, Allan; Barwick, Don; Bertz, Mark; Bielamowicz, Marvin; Bruner Jr., Homer; Clement, Weldon; Cutler, John E.; Dew, Tom; Duncan, Debra; Ellerbrock, Joseph A.; Enloe, David; Eslaminejad, Saeed; Evans, Gordon; Ferguson, Jim; Fossum, Theresa W.; Fox, Russell D.; Frosch, Charles; Gay, Vergel L.; Giroir, Brett; Glowacki, Joe ; Godkin, Blake S.; Goworek, Bob; Hall, Ken; hansen, Bob; Happ, John; Harrison, James B.; Hartman, Robert L.; Hassan, Anwar; Hodge, Steve; Holtz, Barry; Karr, Bruce; Kay, Mack ; Khalsa, Guruatma; Kornberg, Daniel M. ; Krause, Clayton; Kwak W. M. D. Ph. D., Larry ; Lasarsky, Phil; Lauderback, Truman; Mahendra, Anu; Mann, George; McCready, Scott; McGoogan, Cal ; McGraw, Kristopher; Menchaca, Eddie; Mendyk ,Joseph K.; Meyer, Chris; Meyer, Robert J.; Mironova, Lyudmila; Mooney, Catherine; Moustapha, Harb ; Noynaert, Chris ; Parikh, Vimal; Perez, Eric; Peters, Brett; Pishko, Michael; Pollard, Claudia; Rainer, James B;

Ramirez, René; Ravey, Linda; Rhea, Chuck M.; Riley, Jim; Salsman, John M; Sanchez, Jeana F.; Sappington, Mark ; Scannon, Patrick (Pat) J.; Schmid, Peter; Shanahan, David; Shanks, LauraLee M.; Sippial, Charles A; Slaney, Scott; Swick, Les; Tenerowicz, Rob ; Trowbridge, Allan; Wallace, Russell E.; Williams, Belinda; Williams, Les; Williams, Richard; Wurbs, Frank

**Subject:** RE: Schematic Design and Project Schedule Meeting for NCTM

Team,

Please find attached the latest Open Issues List "MM2009-11-16OpenIssues" for the NCTM project. As Brett C. noted, please do your best to complete any action item(s) assigned to you by the Required Date indicated. It is also important that we try to close any Overdue items, especially if they are indicated as Critical Path tasks.

<<MM2009-11-16OpenIssues.pdf>>

Thank you,

Dan

Daniel E. Rosenberg, Architect

Senior Associate, AIA, LEED AP

619 231 0751

[www.fobarch.com](http://www.fobarch.com)



701 B STREET SUITE 200 SAN DIEGO CA 92101

-----Original Appointment-----

**From:** Cumpton, J. Brett [<mailto:Brett-Cumpton@tamu.edu>]

**Sent:** Monday, November 16, 2009 8:53 AM

**To:** FPC Projects: 01-3046 National Center for Therapeutics Manufacturing; Whitney, Bruce; Anderson, Bruce; Baron, Allan; Barwick, Don; Bertz, Mark; Bielasowicz, Marvin; Bruner Jr., Homer; Clement, Weldon; Cumpton, J. Brett; Cutler, John E.; Dew, Tom; Duncan, Debra; Ellerbrock, Joseph A.; Enloe, David; Eslaminejad, Saeed; Evans, Gordon; Ferguson, Jim; Fossum, Theresa W.; Fox, Russell D.; Frosch, Charles; Gay, Vergel L.; Giroir, Brett; Glowacki, Joe ; Godkin, Blake S.; Goworek, Bob; Hall, Ken; Hansen, Bob; Happ, John; Harrison, James B.; Hartman, Robert L.; Hassan, Anwar; Hodge, Steve; Holtz, Barry; Karr, Bruce; Kay, Mack ; Khalsa, Guratma; Kornberg, Daniel M. ; Krause, Clayton; Kwak W. M. D. Ph. D., Larry ; Lasarsky, Phil; Lauderback, Truman; Mahendra, Anu; Mann, George; McCready, Scott; McGoogan, Cal ; McGraw, Kristopher; Menchaca, Eddie; Mendyk ,Joseph K.; Meyer, Chris; Meyer, Robert J.; Mironova, Lyudmila; Mooney, Catherine; Moustapha, Harb ; Noynaert, Chris ; Parikh, Vimal; Perez, Eric; Peters, Brett; Pishko, Michael; Pollard, Claudia; Rainer, James B; Ramirez, René; Ravey, Linda; Rhea, Chuck M.; Riley, Jim; Rosenberg, Dan; Salsman, John M; Sanchez, Jeana F.; Sappington, Mark ; Scannon, Patrick (Pat) J.; Schmid, Peter; Shanahan, David; Shanks, LauraLee M.; Sippial, Charles A; Slaney, Scott; Swick, Les; Tenerowicz, Rob ; Trowbridge, Allan; Wallace, Russell E.; Williams, Belinda;

Williams, Les; Williams, Richard; Wurbs, Frank

**Subject:** Schematic Design and Project Schedule Meeting for NCTM

**When:** Thursday, November 19, 2009 6:30 AM-2:30 PM (GMT-08:00) Pacific Time (US & Canada).

**Where:** FP&C Conference room A

Team,

Please remember to attend the meeting this **Thursday, November 19, 2009 from 8:30 to 4:30** at the TAMU System building in conference room "A".

This will be our 9<sup>th</sup> meeting and will focus on the acceptance of the Schematic Design for the floor plans (for both the Academic and GMP sides of the facility), potential first look at several options for the building's exterior appearance, the latest project schedule, and a brief summary of where we are with the overall project AACC. A more detailed agenda will be sent to each of you prior to the meeting.

This "Open Issues List" should be reviewed by you to determine if the project is waiting for your action on any items.

<<Is2009-10-01 Open Issues List.pdf>>

The "Meeting Minutes" from the last Core team meeting are attached for your review and comment.

<<MM2009-10-29Meeting 8 minutes only.pdf>>

<< File: Is2009-10-01 Open Issues List.pdf >> << File: MM2009-10-29Meeting 8 minutes only.pdf >>

**From:** Robert Tenerowicz  
**To:** Lasarsky, Phil  
**Cc:** Cumpton, J. Brett; Ferguson, Jim; Giroir, Brett; Pat Gannon  
**Subject:** RE: Texas A&M NCTM Process Profiles  
**Date:** Tuesday, June 30, 2009 8:26:12 PM  
**Attachments:** Antibody process 29JUN09.docx

---

Hi Phil,

Likewise, I felt like we accomplished quite a bit in the first meeting.

Enclosed, please find a description of the antibody manufacturing process. Please disregard the formatting as I took this from another document. There's a little bit of information about bacterial production as well - this can be expanded in the future, if needed.

One additional thought: Although we have incorporated quite a bit of disposables technology already, there are additional technologies that we have been evaluating that could add increased efficiency to the antibody manufacturing operation. One such technology is the use of a Q-membrane to replace the Q-SFF column. You should use this in your initial antibody process flow diagram - I've included the advantages to the use of this technology at the end of the enclosed document.

I would suggest that after you've put together the initial document using the current technologies, I'd can highlight areas in the process that could be improved with additional technology advances - these would be technologies that we felt could be available within the next couple years. These advances could affect the sizes of some of the utilities and the footprint of the processing areas that would be needed - i.e., areas where we could possibly save some facility capital expense.

Let me know if you have any questions on any of the enclosed.

Thanks,  
Rob

-----Original Message-----

**From:** Lasarsky, Phil [mailto:[phil.lasarsky@ars.hhs.gov](mailto:phil.lasarsky@ars.hhs.gov)]  
**Sent:** Monday, June 29, 2009 7:01 AM  
**To:** ; Robert Tenerowicz  
**Cc:** Anderson, Bruce; Cumpton, J. Brett; Ferguson, Jim; Giroir, Brett  
**Subject:** Texas A&M NCTM Process Profiles

Gentlemen,

It was great to meet each of you and to have the initial practical dialogue on Thursday concerning the planning of the NCTM. As per our discussions we are tasked with developing process "place holders" for the project. Please provide to me, for the technologies you would consider critical to accommodate in the initial NCTM development, the following:

1. Process narratives (in any format you have)
2. Block flows showing critical processing steps and utility requirements
3. Major equipment list (bioreactors, mix tanks, ultra filters, micro



filters, etc.)

4. Batch timeline through final API fill.

After receiving the information I will formulate a single document including an equipment matrix that can provide the space, environmental and utility requirements for the equipment bundles. It would be good against our two week schedule to get the information by week's end if at all possible.

I have attached an example package.

Thanks in advance for your support and effort.

Phil Lasarsky  
X-Nth  
principal

This message from X-nth has been scanned for malware by Websense and is safe to open. [www.websense.com](http://www.websense.com)

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

**From:** Giroir, Brett  
**To:** Cal McGoogan  
**Cc:** Cumpton, J. Brett; "Steve Engle"; "Pat Scannon"; Anderson, Greg  
**Subject:** RE: XOMA Update  
**Date:** Friday, October 09, 2009 12:40:25 PM

---

Cal:

Thank you sincerely for this update. We have been watching with great hope that XOMA's progress will continue, and that the XOMA's products will continue successfully down the pipeline. We greatly appreciate your ongoing collaboration and consultation.

Best

Brett

Brett P. Giroir, MD

Vice Chancellor for Research,

The Texas A&M University System;

Research Professor, Dwight Look College of Engineering;

Adjunct Professor, The Bush School of Government and Public Service;

200 Technology Way, Suite 2043

College Station, Texas 77845-3424

Phone: 979-458-6054

Fax: 979-458-6044

---

**From:** Cal McGoogan [mailto:[cal.mcgoogan@xoma.com](mailto:cal.mcgoogan@xoma.com)]  
**Sent:** Friday, October 09, 2009 10:43 AM  
**To:** Giroir, Brett  
**Cc:** Cumpton, J. Brett; Steve Engle; Pat Scannon  
**Subject:** XOMA Update  
**Importance:** High

Dear Dr. Giroir,

We at XOMA would like to reiterate our continued support and interest in the National Center for Therapeutics Manufacturing at Texas A&M. This is a facility that will have much benefit for us going forward.

I wanted to update you on a few recent events that are very positive for XOMA going forward. First, as you and I have discussed, XOMA eliminated our outstanding debt to Goldman Sachs. This will be a big help to us going forward. We have also raised more than \$70 Million in the past few months to ensure we are on sound financial footing. These events have provided stability and confidence in our future.

Specifically, XOMA has multiple revenue streams resulting from the licensing of our antibody technologies, development collaborations, product royalties and government contracts. As I

mentioned, the Company announced the full repayment of its \$42 Million loan from Goldman Sachs on September 24. This had been the primary reason for the "Going Concern" qualification received from our corporate auditors. On September 30, we announced a \$13.9 Million financing, which together with our cash reserves, the funding sources mentioned above, and a XOMA 052 corporate partnership deal, are expected to provide sufficient resources to meet the Company's anticipated cash needs into 2011. XOMA has raised over \$48 Million through the sale of equity and \$35 Million from technology licenses during the first nine months of 2009.

We are working diligently with our accounting audit firm to eliminate the "Going Concern". We hope to have this taken care of sooner rather than later, and I will update you with those results.

We are excited by the prospects that our two groups can achieve by working together, and we look forward to doing so.

Best regards,

Cal McGoogan

Vice President, Quality and Facilities

XOMA (US) LLC

---

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, ~~disclosure,~~ distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.

**From:** Giroir, Brett  
**To:** "Rosenberg, Dan"; Cumpton, J. Brett; FPC Projects: 01-3046 National Center for Therapeutics Manufacturing; Whitney, Bruce; "Anderson, Bruce"; Baron, Allan; Barwick, Don; Bertz, Mark; Bielasowicz, Marvin; Bruner Jr., Homer; "Clement, Weldon"; "Cutler, John E."; Dew, Tom; "Duncan, Debra"; Ellerbrock, Joseph A.; "Enloe, David"; "Eslaminejad, Saeed"; Evans, Gordon; "Ferguson, Jim"; Fossum, Theresa W.; Fox, Russell D.; Frosch, Charles; Gay, Vergel L.; "Glowacki, Joe"; "Godkin, Blake S."; "Goworek, Bob"; Hall, Ken; "hansen, Bob"; Happ, John; "Harrison, James B."; Hartman, Robert L.; "Hassan, Anwar"; Hodge, Steve; "Holtz, Barry"; Karr, Bruce; "Kay, Mack"; Khalsa, Gurmatma; "Kornberg, Daniel M."; "Krause, Clayton"; "Kwak W. M. D. Ph. D., Larry"; "Lasarsky, Phil"; "Lauderback, Truman"; "Mahendra, Anu"; Mann, George; "McCready, Scott"; "McGoogan, Cal"; "McGraw, Kristopher"; Menchaca, Eddie; "Mendyk, Joseph K."; Meyer, Chris; Meyer, Robert J.; "Mironova, Lyudmila"; Mooney, Catherine; "Moustapha, Harb"; "Noynaert, Chris"; "Parikh, Vimal"; "Perez, Eric"; Peters, Brett; Pishko, Michael; Pollard, Claudia; Rainer, James B.; Ramirez, René; Ravey, Linda; Rhea, Chuck M.; Riley, Jim; Salsman, John M.; Sanchez, Jeana F.; "Sappington, Mark"; "Scannon, Patrick (Pat) J."; Schmid, Peter; "Shanahan, David"; Shanks, LauraLee M.; Sippial, Charles A.; "Slaney, Scott"; "Swick, Les"; "Tenerowicz, Rob"; "Trowbridge, Allan"; Wallace, Russell E.; "Williams, Belinda"; "Williams, Les"; Williams, Richard; "Wurbs, Frank"  
**Subject:** RE: Schematic Design and Project Schedule Meeting for NCTM  
**Date:** Tuesday, November 17, 2009 4:32:24 PM  
**Attachments:** image001.png

When will we have the most basic 3D design or color mock-up of what this will look like?

Brett P. Giroir, MD  
 Vice Chancellor for Research,  
 The Texas A&M University System;  
 Professor, College of Medicine, Texas A&M Health Science Center;  
 Research Professor, Dwight Look College of Engineering;  
 Adjunct Professor, The Bush School of Government and Public Service;  
 200 Technology Way, Suite 2043  
 College Station, Texas 77845-3424  
 Phone: 979-458-6054  
 Fax: 979-458-6044

---

**From:** Rosenberg, Dan [mailto:  
**Sent:** Monday, November 16, 2009 4:16 PM  
**To:** Cumpton, J. Brett; FPC Projects: 01-3046 National Center for Therapeutics Manufacturing; Whitney, Bruce; Anderson, Bruce; Baron, Allan; Barwick, Don; Bertz, Mark; Bielasowicz, Marvin; Bruner Jr., Homer; Clement, Weldon; Cutler, John E.; Dew, Tom; Duncan, Debra; Ellerbrock, Joseph A.; Enloe, David; Eslaminejad, Saeed; Evans, Gordon; Ferguson, Jim; Fossum, Theresa W.; Fox, Russell D.; Frosch, Charles; Gay, Vergel L.; Giroir, Brett; Glowacki, Joe; Godkin, Blake S.; Goworek, Bob; Hall, Ken; hansen, Bob; Happ, John; Harrison, James B.; Hartman, Robert L.; Hassan, Anwar; Hodge, Steve; Holtz, Barry; Karr, Bruce; Kay, Mack; Khalsa, Gurmatma; Kornberg, Daniel M.; Krause, Clayton; Kwak W. M. D. Ph. D., Larry; Lasarsky, Phil; Lauderback, Truman; Mahendra, Anu; Mann, George; McCready, Scott; McGoogan, Cal; McGraw, Kristopher; Menchaca, Eddie; Mendyk, Joseph K.; Meyer, Chris; Meyer, Robert J.; Mironova, Lyudmila; Mooney, Catherine; Moustapha, Harb; Noynaert, Chris; Parikh, Vimal; Perez, Eric; Peters, Brett; Pishko, Michael; Pollard, Claudia; Rainer, James B.; Ramirez, René; Ravey, Linda; Rhea, Chuck M.; Riley, Jim; Salsman, John M.; Sanchez, Jeana F.; Sappington, Mark; Scannon, Patrick (Pat) J.; Schmid, Peter; Shanahan, David; Shanks, LauraLee M.; Sippial, Charles A.; Slaney, Scott; Swick, Les; Tenerowicz, Rob; Trowbridge, Allan; Wallace, Russell E.; Williams, Belinda; Williams, Les; Williams, Richard; Wurbs, Frank  
**Subject:** RE: Schematic Design and Project Schedule Meeting for NCTM

Team,

Please find attached the latest Open Issues List "MM2009-11-16OpenIssues" for the

NCTM project. As Brett C. noted, please do your best to complete any action item(s) assigned to you by the Required Date indicated. It is also important that we try to close any Overdue items, especially if they are indicated as Critical Path tasks.

<<MM2009-11-16OpenIssues.pdf>>

Thank you,

Dan

Daniel E. Rosenberg, Architect

Senior Associate, AIA, LEED AP

619 231 0751

[www.fobarch.com](http://www.fobarch.com)



701 B STREET SUITE 200 SAN DIEGO CA 92101

-----Original Appointment-----

**From:** Cumpton, J. Brett [<mailto:Brett-Cumpton@tamu.edu>]

**Sent:** Monday, November 16, 2009 8:53 AM

**To:** FPC Projects: 01-3046-National Center for Therapeutics Manufacturing; Whitney, Bruce; Anderson, Bruce; Baron, Allan; Barwick, Don; Bertz, Mark; Bielamowicz, Marvin; Bruner Jr., Homer; Clement, Weldon; Cumpton, J. Brett; Cutler, John E.; Dew, Tom; Duncan, Debra; Ellerbrock, Joseph A.; Enloe, David; Eslaminejad, Saeed; Evans, Gordon; Ferguson, Jim; Fossum, Theresa W.; Fox, Russell D.; Frosch, Charles; Gay, Vergel L.; Giroir, Brett; Glowacki, Joe ; Godkin, Blake S.; Goworek, Bob; Hall, Ken; hansen, Bob; Happ, John; Harrison, James B.; Hartman, Robert L.; Hassan, Anwar; Hodge, Steve; Holtz, Barry; Karr, Bruce; Kay, Mack ; Khalsa, Guruatma; Kornberg, Daniel M. ; Krause, Clayton; Kwak W. M. D. Ph. D., Larry ; Lasarsky, Phil; Lauderback, Truman; Mahendra, Anu; Mann, George; McCready, Scott; McGoogan, Cal ; McGraw, Kristopher; Menchaca, Eddie; Mendyk ,Joseph K.; Meyer, Chris; Meyer, Robert J.; Mironova, Lyudmila; Mooney, Catherine; Moustapha, Harb ; Noynaert, Chris ; Parikh, Vimal; Perez, Eric; Peters, Brett; Pishko, Michael; Pollard, Claudia; Rainer, James B; Ramirez, René; Ravey, Linda; Rhea, Chuck M.; Riley, Jim; Rosenberg, Dan; Salsman, John M; Sanchez, Jeana F.; Sappington, Mark ; Scannon, Patrick (Pat) J.; Schmid, Peter; Shanahan, David; Shanks, LauraLee M.; Sippial, Charles A; Slaney, Scott; Swick, Les; Tenerowicz, Rob ; Trowbridge, Allan; Wallace, Russell E.; Williams, Belinda; Williams, Les; Williams, Richard; Wurbs, Frank

**Subject:** Schematic Design and Project Schedule Meeting for NCTM

**When:** Thursday, November 19, 2009 6:30 AM-2:30 PM (GMT-08:00) Pacific Time (US & Canada).

**Where:** FP&C Conference room A

Team,

Please remember to attend the meeting this **Thursday, November 19, 2009 from 8:30 to 4:30** at the TAMU System building in conference room "A". This will be our 9<sup>th</sup> meeting and will focus on the acceptance of the Schematic Design for the floor plans (for both the Academic and GMP sides of the facility), potential first look at

several options for the building's exterior appearance, the latest project schedule, and a brief summary of where we are with the overall project AACC. A more detailed agenda will be sent to each of you prior to the meeting.

This "Open Issues List" should be reviewed by you to determine if the project is waiting for your action on any items.

<<ls2009-10-01 Open Issues List.pdf>>

The "Meeting Minutes" from the last Core team meeting are attached for your review and comment.

<<MM2009-10-29Meeting 8 minutes only.pdf>>

<< File: ls2009-10-01 Open Issues List.pdf >> << File: MM2009-10-29Meeting 8 minutes only.pdf >>

**To:** Cumpton, J. Brett  
**From:** Cumpton, J. Brett; Steve Engle; Pat Scannon  
**Cc:** XOMA Update  
**Subject:** Friday, October 09, 2009 10:43:05 AM  
**Date:** Friday, October 09, 2009 10:43:05 AM  
**Importance:** High

---

Dear Dr. Giroir,

We at XOMA would like to reiterate our continued support and interest in the National Center for Therapeutics Manufacturing at Texas A&M. This is a facility that will have much benefit for us going forward.

I wanted to update you on a few recent events that are very positive for XOMA going forward. First, as you and I have discussed, XOMA eliminated our outstanding debt to Goldman Sachs. This will be a big help to us going forward. We have also raised more than \$70 Million in the past few months to ensure we are on sound financial footing. These events have provided stability and confidence in our future.

Specifically, XOMA has multiple revenue streams resulting from the licensing of our antibody technologies, development collaborations, product royalties and government contracts. As I mentioned, the Company announced the full repayment of its \$42 Million loan from Goldman Sachs on September 24. This had been the primary reason for the "Going Concern" qualification received from our corporate auditors. On September 30, we announced a \$13.9 Million financing, which together with our cash reserves, the funding sources mentioned above, and a XOMA 052 corporate partnership deal, are expected to provide sufficient resources to meet the Company's anticipated cash needs into 2011. XOMA has raised over \$48 Million through the sale of equity and \$35 Million from technology licenses during the first nine months of 2009.

We are working diligently with our accounting audit firm to eliminate the "Going Concern". We hope to have this taken care of sooner rather than later, and I will update you with those results.

We are excited by the prospects that our two groups can achieve by working together, and we look forward to doing so.

Best regards,

Cal McGoogan

Vice President, Quality and Facilities

XOMA (US) LLC

---

The information contained in this email message may contain confidential or legally privileged information and is intended solely for the use of the named recipient(s). No confidentiality or privilege is waived or lost by any transmission error. If the reader of this message is not the intended recipient, please immediately delete the e-mail and all copies of it from your system, destroy any hard copies of it and notify the sender either by telephone or return e-mail. Any direct or indirect use, disclosure, distribution, printing, or copying of any part of this message is prohibited. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorized to state them to be the views of XOMA.